A Randomized Phase II, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Efficacy and Safety of INC280 in Adult Patients With Advanced Hepatocellular Carcinoma After Progression or Intolerance to Sorafenib Treatment
Status: Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 15 Sep 2016
Price : $35 *
At a glance
- Drugs Capmatinib (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- Sponsors Novartis
- 30 Aug 2016 Status changed from suspended to withdrawn prior to enrolment.
- 13 Dec 2013 Planned End Date changed from 1 Mar 2016 to 1 Sep 2016 as reported by ClinicalTrials.gov.
- 13 Dec 2013 Planned initiation date changed from 1 Feb 2014 to 1 Mar 2014 as reported by ClinicalTrials.gov.